Status: Recruiting
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.
Participants needed: 96
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Shanghai Yuyao Biotech Co., Ltd.Updated: Jan 31, 2024Locations: 1
Eligibility criteria
1.Patients fully understand and sign ICF, voluntarily participate in the study,... [+15]
1. The adverse reactions of previous antineoplastic therapy have not recovered t... [+25]